Recursion Pharmaceuticals, Inc. (RXRX) KPIs and segments
Close on Nov 16, 2026Market cap $1.56BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Recursion Pharmaceuticals's business
Recursion Pharmaceuticals's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Kingdom($M) | 18.6 | 4.07 | 7.31 | 5.34 | 1.14 | 0 | 0 | 0 | |||||
United States($M) | 17.0 | 1.11 | 11.8 | 9.48 | 3.08 | 26.1 | 14.4 | 13.5 | |||||
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-05.
See a number that looks wrong?